Share Price and Basic Stock Data
Last Updated: December 12, 2025, 6:50 pm
| PEG Ratio | 2.84 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Torrent Pharmaceuticals Ltd, a prominent player in the Indian pharmaceutical sector, has shown a robust growth trajectory. For the fiscal year ending March 2025, the company’s revenue from operations stood at ₹11,516 Cr, reflecting a healthy increase from ₹10,728 Cr in the previous fiscal year. This upward trend in sales is notable, with quarterly revenues climbing from ₹2,491 Cr in March 2023 to ₹2,745 Cr by March 2024, and further to ₹2,959 Cr in June 2025. The consistency in revenue growth illustrates Torrent’s ability to navigate market challenges effectively, positioning it as a competitive force within the industry. Additionally, the company’s Operating Profit Margin (OPM) has improved to 32% for FY 2025, up from 30% in FY 2023, underscoring operational efficiency and effective cost management. With a market capitalization of ₹1,28,126 Cr, Torrent’s financial health appears solid, attracting attention from both institutional and retail investors alike.
Profitability and Efficiency Metrics
Profitability metrics for Torrent Pharmaceuticals reflect a commendable performance. The reported net profit of ₹1,911 Cr for FY 2025 is an increase from ₹1,656 Cr in the previous year, showcasing a sustained profit growth trend. The company’s Earnings Per Share (EPS) has also risen significantly, reaching ₹56.47 in FY 2025, compared to ₹48.94 in FY 2024. Furthermore, Torrent’s Return on Equity (ROE) stood at 25.17%, indicating efficient utilization of shareholder funds. The efficiency of operations is further illustrated by the company’s Return on Capital Employed (ROCE), which rose to 28.71% in FY 2025. While these figures are impressive, the company’s P/E ratio of 59.1 does suggest that the stock may be perceived as overvalued compared to historical averages, indicating a potential concern for value-conscious investors.
Balance Sheet Strength and Financial Ratios
Torrent Pharmaceuticals exhibits a strong balance sheet, characterized by a healthy debt-to-equity ratio of 0.39, which indicates that the company is not overly reliant on debt financing. Total borrowings have declined to ₹2,822 Cr, down from ₹5,369 Cr in FY 2023, reflecting prudent financial management and a focus on reducing leverage. The company’s current ratio of 1.19 suggests that it has sufficient liquidity to cover its short-term obligations, which is reassuring for investors. Additionally, with reserves totaling ₹8,280 Cr, Torrent appears well-capitalized to support future growth initiatives. However, the price-to-book value ratio of 14.42x raises questions about the stock’s valuation relative to its book value, potentially indicating that investors are pricing in significant future growth expectations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Torrent Pharmaceuticals reveals a stable yet concentrated ownership structure. Promoters hold 68.31% of the equity, which provides a strong alignment of interests between management and shareholders. Foreign Institutional Investors (FIIs) have increased their stake to 15.92%, suggesting growing confidence from international investors in Torrent’s growth prospects. Conversely, Domestic Institutional Investors (DIIs) hold 9.17% of the company, which is relatively modest. The overall number of shareholders has fluctuated, with 78,226 registered investors as of September 2025, indicating a steady interest in the stock. However, the declining public shareholding to 6.47% raises concerns about liquidity and may deter some retail investors who prefer a more dispersed ownership structure.
Outlook, Risks, and Final Insight
Looking ahead, Torrent Pharmaceuticals seems well-positioned for continued growth, but several risks loom on the horizon. The high P/E ratio suggests that the stock may be vulnerable to market corrections if the company fails to meet growth expectations. Additionally, while the reduction in debt is a positive sign, any future capital needs could lead to increased borrowing, potentially affecting financial stability. Regulatory challenges in the pharmaceutical industry also pose a risk, as compliance issues can lead to costly delays. On the flip side, Torrent’s strong operational metrics and commitment to R&D could drive innovation and market share gains. Investors should weigh these factors carefully, considering both the potential for upside and the inherent risks in an evolving market landscape. Overall, while Torrent Pharmaceuticals presents a compelling investment case, discerning investors should remain vigilant and consider their risk tolerance before making any commitments.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 239/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,249 Cr. | 390 | 479/192 | 88.0 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.1 Cr. | 44.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.1 | 31.0/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,474.95 Cr | 1,156.60 | 51.99 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,347 | 2,291 | 2,491 | 2,491 | 2,591 | 2,660 | 2,732 | 2,745 | 2,859 | 2,889 | 2,809 | 2,959 | 3,178 |
| Expenses | 1,635 | 1,612 | 1,767 | 1,764 | 1,800 | 1,835 | 1,863 | 1,862 | 1,955 | 1,950 | 1,895 | 1,995 | 2,146 |
| Operating Profit | 712 | 679 | 724 | 727 | 791 | 825 | 869 | 883 | 904 | 939 | 914 | 964 | 1,032 |
| OPM % | 30% | 30% | 29% | 29% | 31% | 31% | 32% | 32% | 32% | 32% | 33% | 33% | 32% |
| Other Income | 30 | 16 | -10 | 9 | 34 | 26 | 55 | 31 | 24 | -16 | 33 | -42 | -37 |
| Interest | 55 | 69 | 102 | 107 | 103 | 91 | 80 | 80 | 75 | 64 | 57 | 56 | 56 |
| Depreciation | 155 | 163 | 193 | 196 | 191 | 201 | 213 | 203 | 197 | 198 | 199 | 201 | 201 |
| Profit before tax | 532 | 463 | 419 | 433 | 531 | 559 | 631 | 631 | 656 | 661 | 691 | 665 | 738 |
| Tax % | 33% | 33% | 30% | 34% | 29% | 31% | 30% | 29% | 30% | 31% | 27% | 25% | 26% |
| Net Profit | 354 | 312 | 292 | 287 | 378 | 386 | 443 | 449 | 457 | 453 | 503 | 498 | 548 |
| EPS in Rs | 10.46 | 9.22 | 8.63 | 8.48 | 11.17 | 11.41 | 13.09 | 13.27 | 13.50 | 13.39 | 14.86 | 14.71 | 16.19 |
Last Updated: August 1, 2025, 10:10 am
Below is a detailed analysis of the quarterly data for Torrent Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 3,178.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,959.00 Cr. (Mar 2025) to 3,178.00 Cr., marking an increase of 219.00 Cr..
- For Expenses, as of Jun 2025, the value is 2,146.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,995.00 Cr. (Mar 2025) to 2,146.00 Cr., marking an increase of 151.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 1,032.00 Cr.. The value appears strong and on an upward trend. It has increased from 964.00 Cr. (Mar 2025) to 1,032.00 Cr., marking an increase of 68.00 Cr..
- For OPM %, as of Jun 2025, the value is 32.00%. The value appears to be declining and may need further review. It has decreased from 33.00% (Mar 2025) to 32.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is -37.00 Cr.. The value appears strong and on an upward trend. It has increased from -42.00 Cr. (Mar 2025) to -37.00 Cr., marking an increase of 5.00 Cr..
- For Interest, as of Jun 2025, the value is 56.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 56.00 Cr..
- For Depreciation, as of Jun 2025, the value is 201.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 201.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 738.00 Cr.. The value appears strong and on an upward trend. It has increased from 665.00 Cr. (Mar 2025) to 738.00 Cr., marking an increase of 73.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Mar 2025) to 26.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 548.00 Cr.. The value appears strong and on an upward trend. It has increased from 498.00 Cr. (Mar 2025) to 548.00 Cr., marking an increase of 50.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 16.19. The value appears strong and on an upward trend. It has increased from 14.71 (Mar 2025) to 16.19, marking an increase of 1.48.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:15 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,172 | 4,636 | 6,687 | 5,816 | 5,950 | 7,673 | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 11,516 | 11,835 |
| Expenses | 3,216 | 3,616 | 3,954 | 4,438 | 4,601 | 5,690 | 5,769 | 5,524 | 6,077 | 6,778 | 7,360 | 7,795 | 7,986 |
| Operating Profit | 955 | 1,020 | 2,733 | 1,377 | 1,349 | 1,983 | 2,170 | 2,480 | 2,431 | 2,842 | 3,368 | 3,721 | 3,849 |
| OPM % | 23% | 22% | 41% | 24% | 23% | 26% | 27% | 31% | 29% | 30% | 31% | 32% | 33% |
| Other Income | 34 | 286 | 32 | 223 | 299 | -300 | 121 | 57 | -288 | 45 | 146 | -1 | -62 |
| Interest | 59 | 175 | 184 | 206 | 308 | 504 | 451 | 353 | 255 | 333 | 354 | 252 | 233 |
| Depreciation | 87 | 191 | 238 | 307 | 409 | 618 | 654 | 658 | 662 | 707 | 808 | 795 | 799 |
| Profit before tax | 844 | 940 | 2,343 | 1,088 | 931 | 562 | 1,187 | 1,526 | 1,226 | 1,847 | 2,352 | 2,673 | 2,755 |
| Tax % | 21% | 20% | 26% | 14% | 27% | 22% | 14% | 18% | 37% | 33% | 30% | 28% | |
| Net Profit | 664 | 751 | 1,733 | 934 | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,911 | 2,002 |
| EPS in Rs | 19.62 | 22.19 | 51.22 | 27.59 | 20.04 | 12.89 | 30.28 | 36.99 | 22.97 | 36.79 | 48.94 | 56.47 | 59.15 |
| Dividend Payout % | 25% | 25% | 34% | 25% | 35% | 66% | 53% | 47% | 105% | 60% | 57% | 57% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 13.10% | 130.76% | -46.11% | -27.41% | -35.69% | 135.09% | 22.15% | -37.94% | 60.23% | 33.01% | 15.40% |
| Change in YoY Net Profit Growth (%) | 0.00% | 117.66% | -176.86% | 18.70% | -8.28% | 170.78% | -112.95% | -60.09% | 98.17% | -27.22% | -17.61% |
Torrent Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 8% |
| 3 Years: | 11% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 14% |
| 3 Years: | 21% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 21% |
| 3 Years: | 34% |
| 1 Year: | 5% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 23% |
| 3 Years: | 24% |
| Last Year: | 27% |
Last Updated: September 5, 2025, 1:46 pm
Balance Sheet
Last Updated: December 4, 2025, 2:07 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 |
| Reserves | 1,818 | 2,406 | 3,409 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 | 7,421 | 8,280 |
| Borrowings | 1,132 | 2,740 | 2,352 | 2,510 | 6,462 | 6,038 | 5,784 | 4,874 | 4,070 | 5,369 | 4,022 | 3,202 | 2,822 |
| Other Liabilities | 1,988 | 2,589 | 3,040 | 2,740 | 3,159 | 3,351 | 3,402 | 3,363 | 2,884 | 3,043 | 3,627 | 3,603 | 4,244 |
| Total Liabilities | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 | 15,515 |
| Fixed Assets | 875 | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,121 | 8,138 | 7,947 | 7,841 |
| CWIP | 534 | 678 | 1,042 | 519 | 647 | 617 | 712 | 889 | 630 | 765 | 361 | 478 | 488 |
| Investments | 186 | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 | 156 | 133 |
| Other Assets | 3,427 | 4,011 | 4,206 | 4,589 | 5,249 | 5,395 | 5,763 | 5,940 | 5,628 | 5,524 | 5,834 | 5,815 | 7,053 |
| Total Assets | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 | 15,515 |
Below is a detailed analysis of the balance sheet data for Torrent Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 169.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 169.00 Cr..
- For Reserves, as of Sep 2025, the value is 8,280.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,421.00 Cr. (Mar 2025) to 8,280.00 Cr., marking an increase of 859.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,822.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 3,202.00 Cr. (Mar 2025) to 2,822.00 Cr., marking a decrease of 380.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 4,244.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,603.00 Cr. (Mar 2025) to 4,244.00 Cr., marking an increase of 641.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 15,515.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14,396.00 Cr. (Mar 2025) to 15,515.00 Cr., marking an increase of 1,119.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 7,841.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7,947.00 Cr. (Mar 2025) to 7,841.00 Cr., marking a decrease of 106.00 Cr..
- For CWIP, as of Sep 2025, the value is 488.00 Cr.. The value appears strong and on an upward trend. It has increased from 478.00 Cr. (Mar 2025) to 488.00 Cr., marking an increase of 10.00 Cr..
- For Investments, as of Sep 2025, the value is 133.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Mar 2025) to 133.00 Cr., marking a decrease of 23.00 Cr..
- For Other Assets, as of Sep 2025, the value is 7,053.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,815.00 Cr. (Mar 2025) to 7,053.00 Cr., marking an increase of 1,238.00 Cr..
- For Total Assets, as of Sep 2025, the value is 15,515.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,396.00 Cr. (Mar 2025) to 15,515.00 Cr., marking an increase of 1,119.00 Cr..
Notably, the Reserves (8,280.00 Cr.) exceed the Borrowings (2,822.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 954.00 | -1.00 | 0.00 | -1.00 | -5.00 | -5.00 | -3.00 | -2.00 | -2.00 | -3.00 | -1.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 96 | 125 | 79 | 60 | 77 | 68 | 76 | 69 | 70 | 74 | 63 | 59 |
| Inventory Days | 297 | 275 | 314 | 318 | 429 | 318 | 362 | 456 | 368 | 298 | 310 | 334 |
| Days Payable | 421 | 472 | 523 | 356 | 447 | 345 | 345 | 351 | 250 | 224 | 284 | 239 |
| Cash Conversion Cycle | -28 | -71 | -130 | 21 | 59 | 42 | 93 | 174 | 188 | 147 | 89 | 154 |
| Working Capital Days | 24 | 29 | -1 | 28 | -80 | -62 | -52 | -5 | 7 | -33 | -27 | 7 |
| ROCE % | 35% | 27% | 48% | 19% | 13% | 13% | 15% | 17% | 19% | 20% | 23% | 27% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Large Cap Fund | 3,180,904 | 2.85 | 1132.43 | N/A | N/A | N/A |
| Axis Large Cap Fund | 946,972 | 1 | 337.13 | N/A | N/A | N/A |
| Franklin India Large Cap Fund | 846,654 | 3.8 | 301.42 | N/A | N/A | N/A |
| UTI Flexi Cap Fund | 742,000 | 1.03 | 264.16 | 1,233,512 | 2025-11-03 03:03:49 | -39.85% |
| Kotak Small Cap Fund | 463,748 | 0.92 | 165.1 | N/A | N/A | N/A |
| Canara Robeco Large Cap Fund | 407,164 | 0.84 | 144.95 | N/A | N/A | N/A |
| SBI Healthcare Opportunities Fund | 400,000 | 3.49 | 142.4 | N/A | N/A | N/A |
| HDFC Large and Mid Cap Fund | 336,766 | 0.42 | 119.89 | N/A | N/A | N/A |
| Axis ELSS Tax Saver Fund | 330,930 | 0.33 | 117.81 | N/A | N/A | N/A |
| Nippon India Value Fund | 328,626 | 1.28 | 116.99 | 353,626 | 2025-11-03 03:03:49 | -7.07% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 56.47 | 48.94 | 36.79 | 45.93 | 73.98 |
| Diluted EPS (Rs.) | 56.47 | 48.94 | 36.79 | 45.93 | 73.98 |
| Cash EPS (Rs.) | 79.96 | 72.82 | 57.67 | 85.05 | 112.84 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 224.27 | 202.57 | 183.13 | 351.75 | 344.90 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 224.27 | 202.57 | 183.13 | 351.75 | 344.90 |
| Revenue From Operations / Share (Rs.) | 340.25 | 316.96 | 284.23 | 502.72 | 472.97 |
| PBDIT / Share (Rs.) | 110.63 | 101.21 | 85.30 | 155.27 | 149.90 |
| PBIT / Share (Rs.) | 87.14 | 77.33 | 64.43 | 116.15 | 111.04 |
| PBT / Share (Rs.) | 78.97 | 69.49 | 54.58 | 72.44 | 90.18 |
| Net Profit / Share (Rs.) | 56.47 | 48.94 | 36.79 | 45.92 | 73.97 |
| NP After MI And SOA / Share (Rs.) | 56.47 | 48.94 | 36.79 | 45.92 | 73.97 |
| PBDIT Margin (%) | 32.51 | 31.93 | 30.01 | 30.88 | 31.69 |
| PBIT Margin (%) | 25.61 | 24.39 | 22.66 | 23.10 | 23.47 |
| PBT Margin (%) | 23.20 | 21.92 | 19.20 | 14.40 | 19.06 |
| Net Profit Margin (%) | 16.59 | 15.44 | 12.94 | 9.13 | 15.63 |
| NP After MI And SOA Margin (%) | 16.59 | 15.44 | 12.94 | 9.13 | 15.63 |
| Return on Networth / Equity (%) | 25.17 | 24.15 | 20.09 | 13.05 | 21.44 |
| Return on Capital Employeed (%) | 28.71 | 27.16 | 22.79 | 22.63 | 20.46 |
| Return On Assets (%) | 12.75 | 10.99 | 8.29 | 5.93 | 8.89 |
| Long Term Debt / Equity (X) | 0.15 | 0.23 | 0.40 | 0.35 | 0.50 |
| Total Debt / Equity (X) | 0.39 | 0.57 | 0.85 | 0.67 | 0.82 |
| Asset Turnover Ratio (%) | 0.76 | 0.71 | 0.68 | 0.53 | 0.50 |
| Current Ratio (X) | 1.19 | 1.03 | 0.97 | 1.20 | 1.13 |
| Quick Ratio (X) | 0.65 | 0.61 | 0.56 | 0.64 | 0.58 |
| Inventory Turnover Ratio (X) | 4.70 | 0.73 | 0.63 | 0.68 | 0.69 |
| Dividend Payout Ratio (NP) (%) | 56.66 | 61.29 | 69.30 | 87.09 | 27.03 |
| Dividend Payout Ratio (CP) (%) | 40.02 | 41.19 | 44.21 | 47.02 | 17.72 |
| Earning Retention Ratio (%) | 43.34 | 38.71 | 30.70 | 12.91 | 72.97 |
| Cash Earning Retention Ratio (%) | 59.98 | 58.81 | 55.79 | 52.98 | 82.28 |
| Interest Coverage Ratio (X) | 14.84 | 9.69 | 8.66 | 10.30 | 7.19 |
| Interest Coverage Ratio (Post Tax) (X) | 8.67 | 5.43 | 4.73 | 5.95 | 4.55 |
| Enterprise Value (Cr.) | 111924.90 | 91136.90 | 56758.99 | 50939.27 | 47229.23 |
| EV / Net Operating Revenue (X) | 9.72 | 8.50 | 5.90 | 5.99 | 5.90 |
| EV / EBITDA (X) | 29.89 | 26.60 | 19.66 | 19.38 | 18.62 |
| MarketCap / Net Operating Revenue (X) | 9.51 | 8.21 | 5.41 | 5.56 | 5.37 |
| Retention Ratios (%) | 43.33 | 38.70 | 30.69 | 12.90 | 72.96 |
| Price / BV (X) | 14.42 | 12.84 | 8.39 | 7.95 | 7.37 |
| Price / Net Operating Revenue (X) | 9.51 | 8.21 | 5.41 | 5.56 | 5.37 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.01 | 0.02 |
After reviewing the key financial ratios for Torrent Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
- For Diluted EPS (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
- For Cash EPS (Rs.), as of Mar 25, the value is 79.96. This value is within the healthy range. It has increased from 72.82 (Mar 24) to 79.96, marking an increase of 7.14.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 224.27. It has increased from 202.57 (Mar 24) to 224.27, marking an increase of 21.70.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 224.27. It has increased from 202.57 (Mar 24) to 224.27, marking an increase of 21.70.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 340.25. It has increased from 316.96 (Mar 24) to 340.25, marking an increase of 23.29.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 110.63. This value is within the healthy range. It has increased from 101.21 (Mar 24) to 110.63, marking an increase of 9.42.
- For PBIT / Share (Rs.), as of Mar 25, the value is 87.14. This value is within the healthy range. It has increased from 77.33 (Mar 24) to 87.14, marking an increase of 9.81.
- For PBT / Share (Rs.), as of Mar 25, the value is 78.97. This value is within the healthy range. It has increased from 69.49 (Mar 24) to 78.97, marking an increase of 9.48.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 56.47. This value is within the healthy range. It has increased from 48.94 (Mar 24) to 56.47, marking an increase of 7.53.
- For PBDIT Margin (%), as of Mar 25, the value is 32.51. This value is within the healthy range. It has increased from 31.93 (Mar 24) to 32.51, marking an increase of 0.58.
- For PBIT Margin (%), as of Mar 25, the value is 25.61. This value exceeds the healthy maximum of 20. It has increased from 24.39 (Mar 24) to 25.61, marking an increase of 1.22.
- For PBT Margin (%), as of Mar 25, the value is 23.20. This value is within the healthy range. It has increased from 21.92 (Mar 24) to 23.20, marking an increase of 1.28.
- For Net Profit Margin (%), as of Mar 25, the value is 16.59. This value exceeds the healthy maximum of 10. It has increased from 15.44 (Mar 24) to 16.59, marking an increase of 1.15.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.59. This value is within the healthy range. It has increased from 15.44 (Mar 24) to 16.59, marking an increase of 1.15.
- For Return on Networth / Equity (%), as of Mar 25, the value is 25.17. This value is within the healthy range. It has increased from 24.15 (Mar 24) to 25.17, marking an increase of 1.02.
- For Return on Capital Employeed (%), as of Mar 25, the value is 28.71. This value is within the healthy range. It has increased from 27.16 (Mar 24) to 28.71, marking an increase of 1.55.
- For Return On Assets (%), as of Mar 25, the value is 12.75. This value is within the healthy range. It has increased from 10.99 (Mar 24) to 12.75, marking an increase of 1.76.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.15. This value is below the healthy minimum of 0.2. It has decreased from 0.23 (Mar 24) to 0.15, marking a decrease of 0.08.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.39. This value is within the healthy range. It has decreased from 0.57 (Mar 24) to 0.39, marking a decrease of 0.18.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has increased from 0.71 (Mar 24) to 0.76, marking an increase of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.19. This value is below the healthy minimum of 1.5. It has increased from 1.03 (Mar 24) to 1.19, marking an increase of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has increased from 0.61 (Mar 24) to 0.65, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.70. This value is within the healthy range. It has increased from 0.73 (Mar 24) to 4.70, marking an increase of 3.97.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 56.66. This value exceeds the healthy maximum of 50. It has decreased from 61.29 (Mar 24) to 56.66, marking a decrease of 4.63.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 40.02. This value is within the healthy range. It has decreased from 41.19 (Mar 24) to 40.02, marking a decrease of 1.17.
- For Earning Retention Ratio (%), as of Mar 25, the value is 43.34. This value is within the healthy range. It has increased from 38.71 (Mar 24) to 43.34, marking an increase of 4.63.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 59.98. This value is within the healthy range. It has increased from 58.81 (Mar 24) to 59.98, marking an increase of 1.17.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 14.84. This value is within the healthy range. It has increased from 9.69 (Mar 24) to 14.84, marking an increase of 5.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.67. This value is within the healthy range. It has increased from 5.43 (Mar 24) to 8.67, marking an increase of 3.24.
- For Enterprise Value (Cr.), as of Mar 25, the value is 111,924.90. It has increased from 91,136.90 (Mar 24) to 111,924.90, marking an increase of 20,788.00.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.72. This value exceeds the healthy maximum of 3. It has increased from 8.50 (Mar 24) to 9.72, marking an increase of 1.22.
- For EV / EBITDA (X), as of Mar 25, the value is 29.89. This value exceeds the healthy maximum of 15. It has increased from 26.60 (Mar 24) to 29.89, marking an increase of 3.29.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.51. This value exceeds the healthy maximum of 3. It has increased from 8.21 (Mar 24) to 9.51, marking an increase of 1.30.
- For Retention Ratios (%), as of Mar 25, the value is 43.33. This value is within the healthy range. It has increased from 38.70 (Mar 24) to 43.33, marking an increase of 4.63.
- For Price / BV (X), as of Mar 25, the value is 14.42. This value exceeds the healthy maximum of 3. It has increased from 12.84 (Mar 24) to 14.42, marking an increase of 1.58.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.51. This value exceeds the healthy maximum of 3. It has increased from 8.21 (Mar 24) to 9.51, marking an increase of 1.30.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Torrent Pharmaceuticals Ltd:
- Net Profit Margin: 16.59%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 28.71% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 25.17% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.67
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.65
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 59.2 (Industry average Stock P/E: 51.99)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.39
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.59%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Torrent House, Off Ashram Road, Ahmedabad Gujarat 380009 | investorservices@torrentpharma.com http://www.torrentpharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sudhir Mehta | Chairman Emeritus |
| Mr. Samir Mehta | Executive Chairman |
| Mr. Aman Samir Mehta | Whole Time Director |
| Mr. Jinal Mehta | Non Executive Director |
| Mr. Manish Mahendra Choksi | Independent Director |
| Mr. Nikhil Khattau | Independent Director |
| Ms. Ameera Shah | Independent Director |
| Ms. Nayantara Bali | Independent Director |
FAQ
What is the intrinsic value of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd's intrinsic value (as of 12 December 2025) is 3163.96 which is 16.56% lower the current market price of 3,792.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,28,242 Cr. market cap, FY2025-2026 high/low of 3,882/2,886, reserves of ₹8,280 Cr, and liabilities of 15,515 Cr.
What is the Market Cap of Torrent Pharmaceuticals Ltd?
The Market Cap of Torrent Pharmaceuticals Ltd is 1,28,242 Cr..
What is the current Stock Price of Torrent Pharmaceuticals Ltd as on 12 December 2025?
The current stock price of Torrent Pharmaceuticals Ltd as on 12 December 2025 is 3,792.
What is the High / Low of Torrent Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Torrent Pharmaceuticals Ltd stocks is 3,882/2,886.
What is the Stock P/E of Torrent Pharmaceuticals Ltd?
The Stock P/E of Torrent Pharmaceuticals Ltd is 59.2.
What is the Book Value of Torrent Pharmaceuticals Ltd?
The Book Value of Torrent Pharmaceuticals Ltd is 250.
What is the Dividend Yield of Torrent Pharmaceuticals Ltd?
The Dividend Yield of Torrent Pharmaceuticals Ltd is 0.84 %.
What is the ROCE of Torrent Pharmaceuticals Ltd?
The ROCE of Torrent Pharmaceuticals Ltd is 27.0 %.
What is the ROE of Torrent Pharmaceuticals Ltd?
The ROE of Torrent Pharmaceuticals Ltd is 26.5 %.
What is the Face Value of Torrent Pharmaceuticals Ltd?
The Face Value of Torrent Pharmaceuticals Ltd is 5.00.